Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes

克里唑蒂尼 医学 肺癌 内科学 间变性淋巴瘤激酶 肿瘤科 融合基因 血液学 胃肠病学 碱性抑制剂 基因 生物 遗传学 恶性胸腔积液
作者
Panwen Tian,Yujie Liu,Hao Zeng,Yuan Tang,Analyn Lizaso,Junyi Ye,Lin Shao,Yalun Li
出处
期刊:Journal of Cancer Research and Clinical Oncology [Springer Science+Business Media]
卷期号:146 (4): 935-944 被引量:29
标识
DOI:10.1007/s00432-019-03116-6
摘要

This study aimed to determine the molecular features and clinical outcomes of young patients with non-small cell lung cancer (NSCLC) harboring ALK fusion genes. We interrogated the genomic profile of 1652 patients with lung cancer who underwent targeted next-generation sequencing to screen for candidate oncogenic drivers using histological specimens acquired from January 2016 to December 2018. ALK fusions were identified in 101 NSCLC patients, and 52 of them were diagnosed before the age of 50 years (52/367, 14.2%). Of the 52 patients with early-onset disease, 22 (42.3%) were male and 43 (82.7%) never smoked; the median patient age was 44 years (range 28–50 years). The most frequently occurring ALK fusion partner was EML4, which was identified in 80.8% (42/52) of young patients. Compared to the older patients, patients with early-onset disease were more likely to harbor EML4-ALK variant 1 (38.5% vs. 14.3%; P = 0.007). We also identified rare ALK fusions, including CHRNA7-ALK, TACR1-ALK, HIP1-ALK, DYSF-ALK and ITGAV-ALK, in patients with early-onset disease, and patients with these fusions responded well to crizotinib treatment. A statistically significant difference was observed in progression-free survival (PFS) between the young patients and older patients who received crizotinib as the first-line therapy (17.5 months vs 9.0 months, P = 0.048). However, the median PFS of young patients harboring concurrent TP53 mutations was only 6.2 months. Unique genetic characteristics were found in ALK-rearranged NSCLC patients with early disease onset, and these patients responded better to crizotinib and had longer PFS compared to patients with later disease onset. However, patients with concomitant TP53 mutations may not have a significant response to treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Luffa完成签到,获得积分10
1秒前
moxi摩西发布了新的文献求助10
2秒前
4秒前
追寻电脑发布了新的文献求助10
4秒前
佳佳佳发布了新的文献求助30
7秒前
脑洞疼应助袁超采纳,获得30
8秒前
潇洒的白凝完成签到,获得积分10
12秒前
123完成签到,获得积分10
13秒前
13秒前
qphys完成签到,获得积分10
14秒前
hyf发布了新的文献求助10
14秒前
mjf111完成签到,获得积分10
17秒前
18秒前
wsj发布了新的文献求助10
18秒前
烟酒不离生完成签到,获得积分10
19秒前
20秒前
Jasper应助xyj6486采纳,获得10
21秒前
21秒前
23秒前
于平川春野完成签到 ,获得积分10
23秒前
汉堡包应助我不吃胡萝卜采纳,获得10
25秒前
25秒前
英姑应助潇湘雪月采纳,获得10
25秒前
Xw发布了新的文献求助10
25秒前
26秒前
种花家的狗狗完成签到,获得积分10
26秒前
wanci应助wsj采纳,获得10
28秒前
李昕123完成签到 ,获得积分10
29秒前
超帅青烟发布了新的文献求助10
29秒前
友好的睫毛完成签到 ,获得积分10
29秒前
量子星尘发布了新的文献求助10
31秒前
木皆完成签到,获得积分10
33秒前
35秒前
ChatGPT发布了新的文献求助10
36秒前
王炎完成签到 ,获得积分10
37秒前
李健的小迷弟应助星星采纳,获得10
37秒前
40秒前
42秒前
43秒前
爱笑晓曼发布了新的文献求助20
46秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989390
求助须知:如何正确求助?哪些是违规求助? 3531487
关于积分的说明 11254109
捐赠科研通 3270153
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809174